AUG 17, 2026 · PHASE 3 TRIAL
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
ClinicalTrials.gov
This is a Phase 3 registry record with no reported results; the study is actively recruiting and outcomes have not yet been posted.
Reported
Planned enrollment868
PhasePHASE 3
Primary endpointDisease-Free Survival (DFS), up to ~78 mont…